Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

COX-2 inhibitors.

Richard C Becker1

  • 1Duke Cardiovascular Thrombosis Center, Duke University Medical Center, Durham, North Carolina 27715, USA. beck021@dcri.duke.edu

Texas Heart Institute Journal
|January 6, 2006
PubMed
Summary
This summary is machine-generated.

COX-2 inhibitors should be used cautiously as second- or third-line treatments for brief periods in low-cardiovascular-risk patients. These drugs increase cardiovascular event risk, which appears dose-related and requires further study regarding therapy duration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

RNA interference targeting factor XI: new and novel approach.

Blood advances·2026
Same author

Antiplatelet Strategies and the Unfinished Story of Thrombosis Prophylaxis.

Circulation research·2026
Same author

Advancing cancer therapeutics: new perspectives on mechanisms, regulatory and policy challenges, and innovative multi-modality strategies for the early detection of cardiotoxicity.

Journal of thrombosis and thrombolysis·2026
Same author

Complementary Targeted Constructs Factor XI/XIa Inhibition.

Blood advances·2026
Same author

Clinical spectrum and mechanistic insights into cardiotoxicity from cancer therapies.

Journal of thrombosis and thrombolysis·2026
Same author

Innovative strategies for early detection of cardiotoxicity: artificial intelligence and multi-modality collaborative models.

Journal of thrombosis and thrombolysis·2026
Same journal

Lyme Carditis and Inflammation-Driven Plaque Erosion Presenting as Sudden Cardiac Arrest.

Texas Heart Institute journal·2025
Same journal

Risk Factors for Development of Stroke in Patients With Continuous-Flow Left Ventricular Assist Device Support as Destination Therapy.

Texas Heart Institute journal·2025
Same journal

Midterm Outcomes of Pediatric Mitral Valvuloplasty for Moderate to Severe Mitral Valve Regurgitation and Associated Risk Factors for Postoperative Deterioration.

Texas Heart Institute journal·2025
Same journal

Navigating the Complexities of Mitral Valve Clipping: Early Severe Mitral Valve Stenosis After Mitral Valve Clipping.

Texas Heart Institute journal·2025
Same journal

The Department of Cardiovascular Anesthesia of The Texas Heart Institute: An Informal History.

Texas Heart Institute journal·2025
Same journal

Contributions of Pathobiological and Translational Science to Understanding and Managing Ischemic Heart Disease: Progress, Impediments, and Future Directions.

Texas Heart Institute journal·2025
See all related articles

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Clinical Trials

Background:

  • COX-2 inhibitors were designed to reduce gastrointestinal toxicity in patients at risk for bleeding ulcers.
  • Despite their original intent, COX-2 inhibitor use has significantly increased among patients with low gastrointestinal risk.
  • COX-2 inhibitors are associated with an increased risk of cardiovascular events.

Purpose of the Study:

  • To evaluate the cardiovascular risks associated with COX-2 inhibitor use.
  • To determine appropriate clinical guidelines for the use of COX-2 inhibitors.
  • To investigate the mechanisms underlying COX-2 inhibitor-induced cardiovascular risk.

Main Methods:

  • Analysis of vascular biology and clinical trial data.
  • Review of large healthcare databases to track COX-2 inhibitor utilization patterns.

Related Experiment Videos

  • Examination of the pathobiology and multifactorial mechanisms contributing to cardiovascular risk.

    • Main Results:

    • COX-2 inhibitors should be considered second- or third-line agents, used for short durations in low-risk cardiovascular patients.
    • Cardiovascular risk associated with COX-2 inhibitors varies by agent and appears dose-related.
    • The relationship between cardiovascular risk and therapy duration requires further investigation, with potential differences between early and long-term risk.

    Conclusions:

    • COX-2 inhibitors increase cardiovascular event risk through mechanisms including altered thromboxane A2 and prostacyclin balance, leading to a prothrombotic environment.
    • Further randomized clinical trials are necessary to fully elucidate the cardiovascular hazards of COX-2 inhibitors in both low- and high-risk populations.
    • Clinical use of COX-2 inhibitors should be limited to specific patient groups and durations to mitigate cardiovascular risks.